Safety and Efficacy of Imidapril in the Treatment of Essential Hypertension | Zendy

Masashi Okamura | Zendy; Susumu Ogawa | Zendy; Sadayoshi Ito | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Efficacy of Imidapril in the Treatment of Essential Hypertension

Author(s) -

Masashi Okamura,

Susumu Ogawa,

Sadayoshi Ito

Publication year - 2011

Publication title -

clinical medicine insights therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.205

H-Index - 9

ISSN - 1179-559X

DOI - 10.4137/cmt.s7662

Subject(s) - bradykinin , medicine , blood pressure , angiotensin converting enzyme , cardiology , renin–angiotensin system , pharmacology , angiotensin receptor blockers , matrix metalloproteinase , essential hypertension , receptor

Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are one of the renin angiotensin system (RAS) inhibitors widely used for the treatment of hypertension. Recently, Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC) meta-analysis showed that ACEIs had the blood pressure independent beneficial effects on coronary heart events. In this review, we summarized our current knowledge about ACEIs especially imidapril and re-evaluated ACEIs among other RAS inhibitors (RASIs) because ACEIs have wide ranges of beneficial effects in addition to the ACE inhibition which other RASIs do not have such as the up-regulation of bradykinin level, substance P level, the inhibition of matrix metalloproteinase (MMP) activity and stabilization of coronary plaque.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research